SCHEMBL15035472

SCHEMBL15035472

Cc1scnc1-c1cc2cnc(Nc3ccc(NC4CCNCC4)cc3)nc2n(C2CCc3ccccc3C2=O)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 14/20 0.40
CCND1 P24385 14/20 0.40
CCNA2 P20248 12/20 0.40
CDK2 P24941 12/20 0.40
FGFR1 P11362 11/20 0.40
FGFR2 P21802 11/20 0.40
FGFR4 P22455 11/20 0.40
FGFR3 P22607 11/20 0.40
CCND2 P30279 2/20 0.37
CCND3 P30281 2/20 0.37
CCNA1 P78396 2/20 0.37
CCNE2 O96020 1/20 0.36
CCNE1 P24864 1/20 0.36
AXL P30530 1/20 0.36
TYRO3 Q06418 1/20 0.36
MERTK Q12866 1/20 0.36
JAK2 O60674 1/20 0.35
BRD4 O60885 1/20 0.35
JAK1 P23458 1/20 0.35
BRD2 P25440 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15035371 0.84 CDK4 (0.39) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL15035418 0.80 CDK4 (0.51) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL15035581 0.79 CDK4 (0.39) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL15041806 0.77 CDK4 (0.52) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL15035291 0.77 RIPK2 (0.42) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL15035350 0.76 CDK4 (0.38) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL15035558 0.76 CDK4 (0.41) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL15035921 0.74 PLK2 (0.38) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL15237005 0.74 JAK2 (0.36) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL15035459 0.74 CDK4 (0.39) CDK4CCND1CCNA2CDK2FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 CDK4 404/4885CCND1 2153/4885CCNA2 2011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.